70 results about "Dermatomyositis" patented technology

Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and / or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacterium and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn's Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hemodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma, Dermatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocytopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave's Disease, Hypothyreoidism, Type 1 Diabetes Mellitus, Addison's Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications, Cataracts, Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations, Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus)), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms, and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig's and Alzheimer's Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.

This invention relates to one anti-extracting nuclear antigen spectrum array to ELISA test agent case for selecting for systematic lupus erythematosus, mixed connective tissue disease, Sjogren syndrome, systemic scleroderma, polymyositis and atrophic arthritis system self immune property antigen ENA spectrum micro array to enzyme immune agent case.

The present invention relates to a Chinese medicine composition, and especially a kind of Chinese medicine composition for treating lupus erythematosus, systemic scieroderm, dermatomyositis, panniculitis, behcets disease and connective tissue disease and its preparation process. The Chinese medicine composition is preferably prepared into dripping pill and soft capsule.

There is disclosed a method of treating various diseases caused by micro-vasculature circulation problems, including, but not limited to, vascular insufficiency, phantom pain, diabetic neuropathy, neuropathic pain, autoimmune / inflammatory diseases (e.g., multiple sclerosis, Parkinson's disease, Crohn's Disease, lupus, rheumatoid arthritis, polymyalgia rheumatica, polymyositis, dermatomyositis, sarcoidosis), urinary retention, lymphoedema, and chronic renal insufficiency. Specifically, there is disclosed a treatment providing an effective amount of an acetyl cholinesterase inhibitor compound (or combination of compounds) to treat one or a plurality of microvasculature diseases.

The invention provides a micro RNA group related to Th17 differentiation. The micro RNA group comprises micro RNA 4426, micro RNA 3615, micro RNA 106b, micro RNA 590 and micro RNA 573. The micro RNA changes remarkably in the Th17 differentiation process and can be used as Th17 control targets for preparing drugs for treating or preventing Th17-related diseases including lupus erythematosus, dermatomyositis, vasculitis, sicca syndromes, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, scleroderma, multiple sclerosis, malaria, solar dermatitis, eczema, leucoderma, psoriasis, atopic dermatitis, lichen planus, diabetes, coronary heart diseases, hyperlipemia and the like. The micro RNA group is sensitive to hydroxychloroquine intervention and can serve as a sensitive index for judgment of the clinical effect of hydroxychloroquine, and the micro RNA is convenient to test clinically and can be rapidly used for judging the clinical effect of hydroxychloroquine.

The invention discloses a colloidal gold chromatography anti-Jo-1 antibody detection test paper and a preparation method thereof. The colloidal gold chromatography anti-Jo-1 antibody detection test paper comprises a sample pad, a combination pad, a cellulose nitrate coated film and a water absorption pad, and the sample pad, the combination pad, the cellulose nitrate coated film and the water absorption pad are pasted on a base plate sequentially from one side of the base plate to the other side of the base plate, wherein the combination pad is coated with a gold-labeled antibody a and a gold-labeled antibody b; and the cellulose nitrate coated film is provided with a detection line and a quality control line, the detection line is coated with a Jo-1 antigen protein, and the quality control line is coated with a gold-labeled antibody c. By adopting indirect immunoassay to introduce the Jo-1 antigen protein in the invention to carry out process optimization on the combination pad and the sample pad, so high sensitivity, high specificity and high accuracy detection performances of the anti-Jo-1 antibody are realized, and a reference basis is provided for the auxiliary diagnosis of dermatomyositis / polymyositis.

A method of prophylactic and / or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and / or treat the disease in the mammal. A composition for treatment of a mammal for a disease caused by Ljungan virus infection including an antiviral compound, antiserum, and an interferon. A method of treatment of a mammal for a disease caused by a Ljungan virus infection.

The invention discloses an anti-human FcepsilonRIalpha subunit monoclonal antibody and application thereof. A hybridoma cell strain producing the monoclonal antibody is collected in China Center for Type Culture Collection, and the collection number thereof is CCTCC NO:201211. The anti-human FcepsilonRIalpha subunit monoclonal antibody prepared by the invention can be combined with a human IgE high-affinity receptor FcepsilonRIalpha, and can be used for detecting FcepsilonRIalpha expression on the surface of a cell; and the monoclonal antibody is of great significance for prevention and treatment of mast cell and basophilic granulocyte related diseases such as allergic dermatitis, dermatomyositis, psoriasis and the like, and has great clinical application value. The hybridoma cell strain provided by the invention is favorable in cell strain growth vigor, uniform in cell body size, muddy or transparent and vigorous in division, and has a proliferative potential of infinite division.

A method of prophylactic and / or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and / or treat the disease in the mammal. A composition for treatment of a mammal for a disease caused by Ljungan virus infection including an antiviral compound, antiserum, and an interferon. A method of treatment of a mammal for a disease caused by a Ljungan virus infection.

The invention belongs to the technical field of biological medicines, and particularly relates to a molecular marker for diagnosing anti-MDA5 positive dermatomyositis and application thereof. The invention relates to an application of a molecular marker in preparation of a diagnostic kit for diagnosing anti-MDA5 positive dermatomyositis. The molecular marker is a serum soluble intercellular adhesion molecule-1 (ICAM-1) and a vascular cell adhesion molecule-1 (VCAM-1). Experiments prove that ICAM-1 and VCAM-1 levels of dermatomyositis patients are higher than those of normal people, the levels of anti-MDA5 antibody positive dermatomyositis serum of the ICAM-1 and VCAM-1 are higher than those of anti-MDA5 antibody negative groups, ICAM-1 and VCAM-1 serve as markers for diagnosing anti-MDA5 positive dermatomyositis, and the problems that in the prior art, an anti-MDA5 antibody detection method is complex, kit manufacturing and standard substance selection are difficult, an immunoprecipitation method is complex in operation, and the detection method cannot be popularized in clinical application. The early detection of the increased adhesion molecule level is beneficial to diagnosis of anti-MDA5 antibody positive dermatomyositis, guidance of next treatment is facilitated, and the risk of disease deterioration and death of dermatomyositis patients is reduced.

The present invention relates to fatty acid analogues of the general formula R1-[xi-CH2]n—COOR2 and in particular to a method of treating inflammatory disorder selected from the group consisting of rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and polymyositis; comprising administering to a mammal in need thereof, an effective amount of tetradecylthioaceticacid or tetradecylselenoacetic acid; or a pharmaceutically acceptable salt thereof.

The invention belongs to the field of biological diagnosis and medicine, and particularly relates to an application of a chemotactic factor CCL8 in preparation of a dermatomyositis condition and prognosis evaluation reagent. According to the invention, a patient plasma specimen for definite diagnosis of dermatomyositis is used as a research object; protein chip detection is carried out; a sample is expanded; a protein chip result is verified by an ELISA method; by combining biochemical indexes and clinical manifestation judgment correlation of patients, it is proved that the blood plasma CCL8level of dermatomyositis patients is remarkably higher than that of healthy people, the expression level of the blood plasma CCL8 is related to the illness state and prognosis of the patients, the blood plasma CCL8 level of dermatomyositis patients effective in treatment is remarkably reduced, and CCL8 can aggravate pulmonary lesions of interstitial pneumonia mice. Therefore, the CCL8 can be usedas a potential biomarker to be applied to a reagent for evaluating the illness state and prognosis of dermatomyositis patients, experimental data and theoretical basis are provided for the applicationof the CCL8 to the illness state and prognosis evaluation of the dermatomyositis patients, and the invention further provides a corresponding kit for evaluating the illness state and prognosis of thedermatomyositis patients.

The invention relates to a kit for determining an anti-Jo-1 antibody. The kit comprises a first reagent, wherein the first reagent comprises a mixture coupled with biotin. The mixture comprises a Jo-1antigen and a tRNA. According to the kit and the detection method for determining anti-Jo-1 antibody, the invention has the advantages of good stability, high sensitivity, good repeatability and thelike; a detection system can realize random sample loading, freely combination and continuously detecting, and the detection time is greatly reduced that 120 tests can be completed within 1 hour; andoperations are simple and convenient, a full automatic detection is truly realized, and the result deviation caused by the operations is avoided. Compared with a traditional method, the detection result of the invention is consistent in conformity, and the detection rate of a Jo-1 antibody positive in dermatomyositis / polymyositis is increased to 35%-40%, furthermore the positive signal value is increased by 10-20%.

The present invention relates to technological process of purifying Jo-1 antigen for diagnosis of multiple myitis / dermatomyositis. The technological process is specific combination of immunoaffinity chromatography and other protein purifying technology. The present invention also relates to the preparation process of Jo-1 immunoaffinity chromatography column, and Jo-1 antigen prepared through the said technological process and with proper biological tissue as material. The present invention also relates to the establishment of high efficiency immunoaffinity chromatography separation condition. The present invention also includes immunoassay kit prepared with purified Jo-1 antigen for clinical application and its application. In addition, the present invention provides one kind of technological way for preparing specific antigen used in detecting other autoimmune diseases.

The invention provides a disease detection kit, the kit includes human IgG (Intravenous Gamma Globulin), Tif1-gamma (transcription intermediary factor 1-gamma) antigen, NXP2 antigen carrier, alkaline phosphatase labeled goat anti-human IgG as second antibody, an anti Tif1-gamma antibody positive comparison product as a contrast, and an anti-NXP2 antibody positive comparison product; and the human IgG, the Tif1-gamma antigen and the NXP2 antigen respectively coats different regions of the carrier. The invention also provides use of the antigen group in preparation of the disease diagnosis kit, the antigen group includes the Tif1-gamma antigen and the NXP2 antigen, and the disease is dermatomyositis merged tumor. The disease detection kit can highly specifically diagnose the dermatomyositis merged tumor by detection of the presence of anti Tif1-gamma antibody and anti-NXP2 antibody, can be used for early diagnosis of the dermatomyositis merged tumor, and has broad application prospects.

The invention relates to traditional Chinese medicine composition for treating dermatomyositis. The traditional Chinese medicine composition comprises raw materials of traditional Chinese medicines in parts by weight as follows: 5-25 parts of donkey-hide gelatin, 5-20 parts of acanthopanax root bark, 10-30 parts of Japanese cayratia herbs, 5-20 parts of long-nosed pit viper, 5-25 parts of dodder seeds, 5-20 parts of duckweed, 2-8 parts of garden balsam, 5-25 parts of desertliving cistanche, 5-20 parts of flatstem milkvetch seeds, 10-30 parts of prepared rehmannia roots, 5-25 parts of wooly datchmanspipe herbs, 10-30 parts of coix seeds, 5-20 parts of morinda roots, 5-20 parts of herbs of variegate ladyslipper, 5-25 parts of glassy ganoderma, 5-20 parts of burdock, 5-20 parts of ephedra herbs, 10-30 parts of European verbena herbs, 5-20 parts of loose knots, 5-20 parts of siegesbeckia herbs and 5-15 parts of liquorice roots. The traditional Chinese medicine composition has effects of tonifying the liver and the kidney, nourishing the spleen, benefiting qi, dispelling the wind, removing dampness, clearing heat, removing toxins, promoting blood circulation, removing meridian obstruction, relaxing tendons and removing pain or numbness, has the significant effect on the dermatomyositis and has the reliable action.

The invention relates to a composition and a method conducive to acquiring follicular regulatory T cells in vitro and an application of the composition. The invention proves that differentiation and number proliferation of in-vitro Tfr (follicular regulatory T cells) can be effectively induced by the aid of irritation of TGF (transforming growth factor)-beta, IL (interleukin)-2, anti-CD3 antibodies, anti-CD28 antibodies and baicalin, and expression of Foxp3 in the Tfr is facilitated. The Tfr cells amplified by the method can be used for treating autoimmune diseases and chronic inflammatory diseases, the autoimmune diseases include lupus erythematosus, dermatomyositis, vasculitides, sicca syndrome, scleroderma, rheumatoid arthritis, ankylosing spondylitis, disseminated sclerosis and autoimmune hepatitis, and the chronic inflammatory diseases include diabetes, coronary heart diseases, hyperlipemia, eczema, vitiligos, atopic dermatitis, lichen planus and the like.

The invention provides a Chinese medicinal composition for treating dermatomyositis. The Chinese medicinal composition comprises the following components in part by weight: 8 to 12 parts of phellodendron, 8 to 12 parts of atractylodes lancea, 9 to 15 parts of fangchi radix, 5 to 7 parts of akebia stem, 28 to 32 parts of coix seed, 9 to 15 parts of silkworm excrement, 9 to 15 parts of twotoothed achyranthes root, 7 to 11 parts of wrinkled gianthyssop herb, 7 to 11 parts of eupatorium fortunei, 7 to 11 parts of officinal magnolia bark, 12 to 18 parts of tuckahoe, and 12 to 18 parts of alisma plantagoaquatica. Compared with the prior art, the Chinese medicinal composition treats dermatomyositis by differentiation of symptoms aiming at the internal pathogenic factors of dermatomyositis, has quick response, and an obvious effect, is low in cost, and does not have toxic or side effects, and addresses both the symptoms and root causes.

The invention discloses a medicinal composition for treating dermatomyositis. The medicinal composition is prepared from the following main raw materials in part by weight: 100 to 200 parts of buffalo horn, 10 to 100 parts of tripterygium wilfordii, 100 to 200 parts of rehmannia root, 10 to 100 parts of rhubarb, 100 to 200 parts of sweet wormwood herb, 100 to 200 parts of red-rooted salvia root, 100 to 200 parts of suberect spatholobus stem, 100 to 200 parts of astragalus, 10 to 100 parts of epimedium herb and 10 to 100 parts of liquoric root. A preparation method for the medicinal composition comprises the following steps of: weighing the raw materials according to a formula, and uniformly mixing the raw materials by crush and water extraction and concentration or in a mode of combining the crush and the water extraction and concentration to obtain the medicinal composition. The medicinal composition can clear heat and cool blood, remove toxicity and dredge collaterals, tonify qi, strengthen the body resistance and nourish blood, and is used for fever, erythema, pain of joints and muscle, swell, laborious activity and the like caused by systemic lupus erythematosus, dermatomyositis and other rheumatism immunological diseases.

The invention provides a traditional Chinese medicine composition containing epimedium powder for treating dermatomyositis and a preparation thereof. The dermatomyositis is classified as 'flaccidity syndrome' by the theory of collateral diseases of the Chinese traditional medicine, and the pathogenesis of the dermatomyositis is mainly the deficiency of the spleen and the kidney, no source for the production and transformation of qi and blood, inability of the weakened body resistance to conquer pathogen, and obstruction of the collaterals of muscles and skin by wind cold dampness, thus affecting the liver, the kidney and the spleen and causing the yin collaterals stasis of internal organs, qi-blood disharmony, and malnutrition of the limbs, skin, tendons and channels. Aiming at treating syndromes of yang deficiency of the liver and the kidney, and obstruction of collaterals by cold dampness due to the dermatomyositis, the traditional Chinese medicine composition determines the treatment based on differentiation of symptoms and signs by using the theory of the collateral diseases of Chinese traditional medicine, and is made from rhizoma curculiginis, the epimedium powder, cassia twig, astragalus root, white atractylodes rhizome, poria, Chinese ephedra, radix aconiti, scorpion, angelica, notopterygium root and heracleum hemsleyanum michaux to warm yang and nourish kidney, invigorate spleen and eliminate dampness and expel cold and activate the channels. Clinical studies prove that the traditional Chinese medicine composition can treat the dermatomyositis effectively.

The invention is concerned with use of oral inorganic pyrophosphate for preventing and / or reducing tissue calcification, particularly soft tissue calcification, and / or diseases or disorders characterized by low plasma PPi levels, as, e.g., occurs in chronic kidney disease (CKD), end-stage renal disease (ESRD), generalized arterial calcification of infancy (GACI), Pseudoxanthoma elasticum (PXE), Arterial Calcification Due to Deficiency of CD73 (ACDC), Ehlers-Danlos syndrome, arteriosclerosis obliterans, venous calcifications, crystal deposition disorders, calcification resulting from neurological disorders, calcinosis universalis, calcinosis circumscripta, scleroderma, dermatomyositis, systemic lupus erythematosus, hyperparathyroidism, neoplasms, milk-alkali syndrome, hypervitaminosis D, tumoral calcinosis, hypophosphatemic rickets, ossification of the posterior longitudinal ligament of the spine, myocardial ischemia, joint calcification, heterotropic ossification of traumatized muscle, angioid streaks, diabetes mellitus type II, cardiovascular disorder, or atherosclerosis.

The invention provides a Chinese medicinal preparation for treating dermatomyositis. The Chinese medicinal preparation comprises the following components in part by weight: 12 to 18 parts of codonopsis pilosula, 9 to 15 parts of bighead atractylodes rhizome, 9 to 15 parts of lentil, 9 to 15 parts of tuckahoe, 2 to 4 parts of cardamom, 5 to 7 parts of pericarpium citri reticulatae, 12 to 18 parts of Chinese yam, 28 to 32 parts of coix seed, 9 to 15 parts of lotus seed, 12 to 18 parts of Chinese taxillus twig, 9 to 15 parts of morinda officinalis, and 9 to 15 parts of twotoothed achyranthes root. Compared with the prior art, the Chinese medicinal preparation treats dermatomyositis by differentiation of symptoms aiming at the internal pathogenic factors of dermatomyositis, has quick response, and an obvious effect, is low in cost, does not have toxic or side effects and can address both the symptoms and root causes.

The invention provides a Chinese medicine for treating dermatomyositis. The Chinese medicine comprises the following components in part by weight: 28 to 32 parts of gypsum, 9 to 15 parts of adenophora elata, 9 to 15 parts of liriope, 7 to 11 parts of folium mori, 7 to 11 parts of almond, 7 to 11 parts of fructus cannabis, 7 to 11 parts of rhizoma anemarrhenae, 9 to 15 parts of honeysuckle flower, 9 to 15 parts of weeping forsythia, 9 to 15 parts of mongolian snakegourd root, 18 to 22 parts of honeysuckle stem, 9 to 15 parts of gentiana macrophylla, 12 to 18 parts of root of rehmannia, and 9 to 15 parts of tree peony bark. Compared with the prior art, the Chinese medicine can treat dermatomyositis by differentiation of symptoms aiming at the internal pathogenic factors of dermatomyositis, has quick response and an obvious effect, is low in cost, does not have toxic or side effects, and can address both the symptoms and root causes.

The invention discloses an anti-human Fc epsilon RI alpha subunit monoclonal antibody and application thereof. A hybridoma cell strain capable of producing the monoclonal antibody is preserved in China Center for Type Culture Collection and has the preservation number of CCTCC NO. C201326. The anti-human Fc epsilon RI alpha monoclonal antibody prepared by the invention can be bound with high-affinity receptor Fc epsilon RI alpha of human IgE and can be applied in detecting the expression of cell surface Fc epsilon RI alpha. The monoclonal antibody has important significance and relatively large clinical value for prevention and treatment of mast cell and basophilic granulocyte-related diseases, such as allergic dermatitis, dermatomyositis and psoriasis. The hybridoma cell strain disclosed by the invention grows well, and is bright and transparent, the cell body is uniform, the division is strong and the hybridoma cell strain has indefinitely divided proliferative capability.

The invention provides a traditional Chinese medicine composition containing cicada shell for treating dermatomyositis and a preparation thereof. The dermatomyositis is classified as 'flaccidity syndrome' by the theory of collateral diseases of the Chinese traditional medicine, and the pathogenesis of the dermatomyositis is mainly the deficiency of the spleen and the kidney, no source for the production and transformation of qi and blood, inability of the weakened body resistance to conquer pathogen, and obstruction of the collaterals of muscles and skin by wind cold dampness, thus affecting the liver, the kidney and the spleen and causing the yin collaterals stasis of internal organs, qi-blood disharmony, and malnutrition of the limbs, skin, tendons and channels. Aiming at treating syndromes of obstruction of channels and collaterals and collateral deficiency caused by pathogen of the dermatomyositis, the traditional Chinese medicine composition determines the treatment based on differentiation of symptoms and signs by the theory of the collateral deficiency of Chinese traditional medicine, and is made from dried rehmannia root, turtle shell, white mustard seed, angelica root, astragalus root, scorpion, spatholobus stem and cicada shell to regulate the nutrient and tonify deficiency, and eliminate the pathogenic factors and activate the channels. Clinical studies prove that the traditional Chinese medicine composition can treat the dermatomyositis effectively.

The invention discloses a formula traditional Chinese medicine for treating dermatosis and belongs to the technical field of traditional Chinese medicines. The formula traditional Chinese medicine comprises an external main formula and an internal auxiliary formula, and has special effects on treating psoriasis, eczema, prurigo nodosa, amyloid lichen, pruritus cutanea, pityriasis rosea, neurodermatitis, rhagadia of hands and feet, contact dermatitis, tinea capitis, tinea manuum, tinea pedis, tinea corporis, tinea versicolor, dermatitis, urticaria, acne and folliculitis. In the traditional Chinese medicine science, the cause of sores and stubborn dermatophytosis is mixture of wind, phlegm fire, dampness and pathogenic toxins. The leading cause of all diseases is wind, trembling and dizziness are caused by lesions of the liver, liver qi is stagnated to generate phlegm fire, the liver transfers malignant infections to spleen, dampness is generated due to spleen deficiency, water is retained in the earth, spleen diseases are transferred to the kidney to cause kidney deficiency, yin and yang imbalance of the human body is caused, and wind, phlegm fire, dampness, pathogenic toxin and deficiency are caused and need to be treated. The medicine can be used in four seasons, has a relatively strong repairing effect on skin epidermis, dermis, subcutaneous tissue and the like, and has the effects of relieving itching and pain, removing necrotic tissue and promoting tissue regeneration, clearing heat and drying dampness, purging fire and removing toxin, cooling blood and removing freckles and the like.

The invention discloses a traditional Chinese medicine preparation for treating dermatomyositis. The traditional Chinese medicine preparation is prepared from the following traditional Chinese medicine preparation raw materials in parts by weight: 45 to 60 parts of rhizoma kaempferiae, 41 to 59 parts of sauropus spatulifolius beille, 33 to 47 parts of rhododendron mariae, 31 to 39 parts of pokeberry root, 25 to 34 parts of alpinia katsumadai, 20 to 31 parts of fritillary bulb, 15 to 24 parts of erigeron breviscapus, 13 to 20 parts of ricepaper pith, 9 to 15 parts of cassia twig and 5 to 11 parts of lithospermum. By adopting the traditional Chinese medicine preparation provided by the invention, clinical symptoms and signs of patients with dermatomyositis can be effectively relieved, the life quality of the patients is improved, and the effects of effect enhancing and toxicity reducing, and condition stabilizing can be effectively realized; the curative effect is significant by using the medicine provided by the invention for treating dermatomyositis, the medicine is simple to prepare and use, has no toxic and side effects and can treat both symptoms and root causes, and the patients have no adverse reactions after using the medicine.

The invention discloses a medicinal composition for treating dermatomyositis. The medicinal composition is prepared from the following main raw materials in part by weight: 100 to 200 parts of buffalo horn, 10 to 100 parts of tripterygium wilfordii, 100 to 200 parts of rehmannia root, 10 to 100 parts of rhubarb, 100 to 200 parts of sweet wormwood herb, 100 to 200 parts of red-rooted salvia root, 100 to 200 parts of suberect spatholobus stem, 100 to 200 parts of astragalus, 10 to 100 parts of epimedium herb and 10 to 100 parts of liquoric root. A preparation method for the medicinal composition comprises the following steps of: weighing the raw materials according to a formula, and uniformly mixing the raw materials by crush and water extraction and concentration or in a mode of combining the crush and the water extraction and concentration to obtain the medicinal composition. The medicinal composition can clear heat and cool blood, remove toxicity and dredge collaterals, tonify qi, strengthen the body resistance and nourish blood, and is used for fever, erythema, pain of joints and muscle, swell, laborious activity and the like caused by systemic lupus erythematosus, dermatomyositis and other rheumatism immunological diseases.

The invention discloses a traditional Chinese medicine preparation for treating dermatomyositis. The traditional Chinese medicine preparation is prepared from the following medicinal materials in parts by weight: 25-36 parts of radix knoxiae, 17-35 parts of processed radix aconiti lateralis, 10-25 parts of red halloysite, 5-17 parts of perfoliote knotweed herb, 10-20 parts of tea prepared from coix chinensis root, 5-11 parts of common clubmoss herb, 3-12 parts of Chinese honeylocust spine, 5-12 parts of root of mountain spicy tree, 10-20 parts of ophicalcite, 12-25 parts of deer-horn glue, 13-26 parts of epimedium wushanense and 11-26 parts of honeysuckle stem. The traditional Chinese medicine preparation disclosed by the invention is a pure traditional Chinese medicine preparation and good in curative effect, has no toxic or side effects, and can effectively take the effects of enhancing effects, decreasing toxicity and stabilizing patient's conditions; for internal pathogenic factors of dermatomyositis, the medicine composition is used for treating on the basis of syndrome differentiation, takes effect quickly, is low in cost and obvious in effect, can treat both symptoms and root causes, and further can be used for treating deficiency of the liver-yin and kidney-yin.